Rhumbline Advisers trimmed its position in Pharmerica Corporation (NYSE:PMC) by 4.2% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 68,099 shares of the company’s stock after selling 2,985 shares during the period. Rhumbline Advisers owned approximately 0.22% of Pharmerica Corporation worth $1,788,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. SG Americas Securities LLC purchased a new position in Pharmerica Corporation in the 1st quarter valued at $121,000. Russell Investments Group Ltd. grew its position in Pharmerica Corporation by 124.5% in the 2nd quarter. Russell Investments Group Ltd. now owns 4,886 shares of the company’s stock valued at $128,000 after buying an additional 2,710 shares during the last quarter. State of Alaska Department of Revenue lifted its holdings in Pharmerica Corporation by 79.8% in the second quarter. State of Alaska Department of Revenue now owns 6,112 shares of the company’s stock valued at $160,000 after acquiring an additional 2,712 shares during the period. US Bancorp DE lifted its holdings in Pharmerica Corporation by 41.3% in the first quarter. US Bancorp DE now owns 7,121 shares of the company’s stock valued at $167,000 after acquiring an additional 2,081 shares during the period. Finally, Mason Street Advisors LLC lifted its holdings in Pharmerica Corporation by 7.0% in the first quarter. Mason Street Advisors LLC now owns 7,200 shares of the company’s stock valued at $168,000 after acquiring an additional 474 shares during the period. Hedge funds and other institutional investors own 92.15% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Rhumbline Advisers Has $1.79 Million Position in Pharmerica Corporation (PMC)” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/09/18/rhumbline-advisers-has-1-79-million-position-in-pharmerica-corporation-pmc.html.

Shares of Pharmerica Corporation (NYSE PMC) opened at 29.05 on Monday. Pharmerica Corporation has a 12-month low of $19.20 and a 12-month high of $29.40. The firm has a 50-day moving average price of $28.73 and a 200-day moving average price of $25.58. The firm has a market cap of $904.07 million, a P/E ratio of 39.36 and a beta of 0.84.

Pharmerica Corporation (NYSE:PMC) last released its quarterly earnings results on Wednesday, August 2nd. The company reported $0.47 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.47. Pharmerica Corporation had a return on equity of 10.94% and a net margin of 1.05%. The company had revenue of $592.00 million during the quarter, compared to analysts’ expectations of $592.96 million. During the same quarter in the prior year, the business posted $0.47 earnings per share. The company’s revenue for the quarter was up 13.9% compared to the same quarter last year. On average, equities research analysts expect that Pharmerica Corporation will post $1.94 earnings per share for the current fiscal year.

A number of equities research analysts have commented on the company. UBS AG reissued a “neutral” rating and issued a $29.25 target price (up previously from $26.00) on shares of Pharmerica Corporation in a report on Thursday, August 3rd. Barrington Research downgraded Pharmerica Corporation from an “outperform” rating to an “underperform” rating in a report on Thursday, August 3rd. KeyCorp downgraded Pharmerica Corporation to an “overweight” rating in a report on Wednesday, August 2nd. Zacks Investment Research downgraded Pharmerica Corporation from a “buy” rating to a “hold” rating in a report on Friday, June 23rd. Finally, Credit Suisse Group downgraded Pharmerica Corporation from an “outperform” rating to a “neutral” rating and raised their target price for the company from $29.00 to $29.25 in a report on Friday, August 4th. They noted that the move was a valuation call. Two analysts have rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the stock. Pharmerica Corporation currently has an average rating of “Hold” and an average price target of $28.83.

Pharmerica Corporation Company Profile

Want to see what other hedge funds are holding PMC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pharmerica Corporation (NYSE:PMC).

Institutional Ownership by Quarter for Pharmerica Corporation (NYSE:PMC)

Receive News & Ratings for Pharmerica Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharmerica Corporation and related companies with MarketBeat.com's FREE daily email newsletter.